MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transci.2024.104057

Медицинская библиотека · Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2024

What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?

Yigenoglu Tugce Nur, Erkurt Mehmet Ali, Dagdas Simten, Ulu Bahar Uncu, Kuku Irfan, Durdu Ali, Pepeler Mehmet Sezgin, Kul Sinem, Dal Mehmet Sinan, Kaya Emin, Korkmaz Serdal, Ulaş Turgay, Altuntas Fevzi

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Acute graft versus host disease (GVHD) occurs in 20-80 % of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of these patients, 40 % will be resistant to steroids, which is the standard first-line approach. There is no standard second line treatment approach for patients with steroid refractory acute GVHD (SR-aGVHD). Alpha-1 antitrypsin is a protease inhibitor and has anti-inflammatory and immune regulatory properties. Here we report the outcomes and safety data of 17 patients treated with alpha-1 antitrypsin for SR-aGVHD.

MATERIAL AND

METHODS

Patients who received at least 2 lines of alpha-1 antitrypsin treatment for SR-aGVHD at five transplant centers in Türkiye were included in this retrospective study.

RESULTS

The median number of alpha-1 antitrypsin treatment line patients received was 4 (range, 2-5). The median time between alpha-1 antitrypsin administration and response was 65 days (range, 10-138 days). Overall response rate was 70.6 %. When the first- and second-month response rates were compared according to GVHD organ involvement, we found that the response rates were similar in skin, liver and gastrointestinal system involvement (p = 0.281 and p = 0.305, respectively). No grade 3-4 anemia, thrombocytopenia or neutropenia was observed after alpha-1 antitrypsin treatment. Two patients had cytomegalovirus infection and 1 patient had pneumonia. At a median follow-up of 7 months, overall survival was 70.6 % and median overall survival was not reached.

CONCLUSION

In conclusion, alpha-1 antitrypsin is an effective and safe treatment option in patients with SR-aGVHD, with response rates of up to 70 % in patients with skin, liver and gastrointestinal system involvement. Larger studies are needed to establish a standard second and subsequent treatment approach in patients with SR-aGVHD.

Для цитирования: Yigenoglu Tugce Nur, Erkurt Mehmet Ali, Dagdas Simten, Ulu Bahar Uncu, Kuku Irfan, Durdu Ali, Pepeler Mehmet Sezgin, Kul Sinem, Dal Mehmet Sinan, Kaya Emin, Korkmaz Serdal, Ulaş Turgay, Altuntas Fevzi. What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2024. DOI: 10.1016/j.transci.2024.104057.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.